Every figure this model derived for HBIO, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.
This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.
| Figure | Value | XBRL tag | As at |
|---|---|---|---|
| capex | 1,770,000 | PaymentsToAcquirePropertyPlantAndEquipment |
2026-06-30 |
| cash | 6,503,000 | CashAndCashEquivalentsAtCarryingValue |
2026-06-30 |
| current assets | 46,463,000 | AssetsCurrent |
2026-06-30 |
| current liabilities | 24,793,000 | LiabilitiesCurrent |
2026-06-30 |
| equity | 7,418,000 | StockholdersEquity |
2026-06-30 |
| interest expense | 4,587,000 | InterestPaidNet |
2026-06-30 |
| ocf | 651,000 | NetCashProvidedByUsedInOperatingActivities |
2026-06-30 |
| revenue | 87,808,000 | RevenueFromContractWithCustomerExcludingAssessedTax |
2026-06-30 |
| sbc | 1,420,000 | ShareBasedCompensation |
2026-06-30 |
The figures themselves rather than their scores — what somebody looking up HBIO on one particular measure came for.
| Ratio | Value |
|---|---|
| cash operating margin | 3.38 |
| current ratio | 2.19 |
| current ratio reported | 1.87 |
| deferred revenue growth | 14.57 |
| dilution pct | 1.96 |
| fcf margin | -1.27 |
| interest cover | -0.05 |
| net debt ebitda | 19.52 |
| operating margin | -0.28 |
| owner earnings margin | -2.89 |
| revenue growth | -1.06 |
| revenue growth per share | -2.96 |
| roic | -0.51 |
| rpo growth | 36.88 |
| rule of 40 | -1.34 |
| sbc pct revenue | 1.62 |
What this model itself distrusts about HBIO's figures. Written by the derivation as it ran, not added afterwards.